Hepatotoxins

City of Hope-Led Research Identifies How the Most Common Type of Breast Cancer Becomes Resistant to Treatment

Retrieved on: 
Thursday, June 24, 2021
Research, Other Health, General Health, Pharmaceutical, Oncology, Consumer, Clinical trials, Science, Biotechnology, Women, Stem cells, Health, Other Science, Endocrine system, Hormones, Organ systems, Breast cancer, Hepatotoxins, Prolactin releasers, Hormone receptor positive breast tumor, Estrogen receptor, Estrogen, Cancer, Estrogen deprivation therapy, Antihormone therapy

City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .

Key Points: 
  • City of Hope, a world-renowned cancer research and treatment center, has identified how cancer cells in patients with early-stage breast cancer change and become resistant to hormone or combination therapies, according to a new study published in Nature Cancer .
  • About 80% of breast cancer cases are hormone receptor positive, meaning that these cancer cells need estrogen or progesterone to grow, according to the American Cancer Society .
  • Doctors currently treat people with estrogen receptor positive (ER+) breast cancer using therapy that inhibits both estrogen levels and cell cycle activity.
  • City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases.

2021 Global Hydrazine Dihydrochloride (CAS 5341-61-7) Market Research Report - Downstream Industry Trends - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 23, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Monoamine oxidase inhibitors, Hydrazines, Hepatotoxins, Chemical substances, Chemistry, Physical sciences, Occupational safety and health, Rocket fuels, Hydrazine, Phenoxypropazine

The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hydrazine dihydrochloride (CAS 5341-61-7) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Hydrazine dihydrochloride.
  • The Hydrazine dihydrochloride global market report key points:
    The first chapter introduces the product (composition, structure, hazards, storage, toxicological & ecological information, etc.).
  • The fifth chapter deals with Hydrazine dihydrochloride market trends and forecast, distinguish Hydrazine dihydrochloride manufacturers and suppliers.

Jounce Therapeutics Provides Update on INNATE Study and Discovery Pipeline Expansion, and Provides a Portfolio Update at 2021 R&D Day

Retrieved on: 
Wednesday, June 23, 2021
Drugs, Organic compounds, Bristol-Myers Squibb, Chloroarenes, Clopidogrel, Hepatotoxins, Prodrugs, Sanofi, Chemical compounds

Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.

Key Points: 
  • Presentations will highlight Jounces productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064.
  • More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064.
  • Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounces broader pipeline.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Centrient Pharmaceuticals boosting statins API manufacturing capacity

Retrieved on: 
Monday, June 21, 2021
Health sciences, Health care, Health, Hepatotoxins, Pharmaceutical industry, Statin, Pharmaceuticals policy, Beta-lactam, β-lactam antibiotic, Pharmaceutical industry in China, Medication

Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.

Key Points: 
  • Centrient Pharmaceuticals has started production at its newly built statins API manufacturing unit in Toansa, India.
  • Using backward integrated manufacturing methods, and dedicated production facilities, Centrient Pharmaceuticals is able to offer its customers security of supply.
  • Centrient Pharmaceuticals (Centrient), the global leader in sustainable antibiotics, next-generation statins and anti-fungals, announced today to have started production at its new statins manufacturing unit.
  • Centrient Pharmaceuticals is the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and antifungals.

Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Retrieved on: 
Monday, June 21, 2021
Medical specialties, Liver, Clinical medicine, Hepatology, Orphan drugs, Cholanes, Hepatotoxins, Obeticholic acid, Cirrhosis, Bilirubin, Intercept Pharmaceuticals

We are also pleased to be presenting new real-world data in PBC at this years Congress, continued Dr. Cawkwell.

Key Points: 
  • We are also pleased to be presenting new real-world data in PBC at this years Congress, continued Dr. Cawkwell.
  • Across groups, Ocaliva produced marked reductions in alkaline phosphatase and bilirubin after both one year and two years of treatment.
  • REGENERATE is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study assessing the safety and efficacy of obeticholic acid (OCA) on clinical outcomes in patients with liver fibrosis due to NASH.
  • A pre-specified 18-month analysis was conducted to assess the effect of OCA on liver histology comparing month 18 biopsies with baseline.

Penn Dental Medicine Study Shows How HIV Infection Impacts Brain's White Matter

Retrieved on: 
Friday, June 18, 2021
Hepatotoxins, Medical specialties, Prevention of HIV/AIDS, Retroviridae, Health, HIV/AIDS, Pandemics, HIV, Oligodendrocyte, Zidovudine, HIV-associated neurocognitive disorder

PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.

Key Points: 
  • PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.
  • Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)the lifesaving drugs that many with HIV use dailycan reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
  • In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production.
  • "Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto , professor at Penn Dental Medicine and the study's co-senior author.

Global $6.94 Billion Ibuprofen (Tablet, Capsule, Syrup and Injection) Markets, Competition Forecast & Opportunities, 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Health, Pharmaceutical, Analgesics, Nonsteroidal anti-inflammatory drugs, Hepatotoxins, Ibuprofen, Racemate, Drugs, IBU, Forecast period, Health care, Chemistry

The Global Ibuprofen Market is expected to grow at a steady rate during the forecast period with a CAGR of 5.67% in value terms to reach USD6945.36 million by 2026.

Key Points: 
  • The Global Ibuprofen Market is expected to grow at a steady rate during the forecast period with a CAGR of 5.67% in value terms to reach USD6945.36 million by 2026.
  • The Global Ibuprofen Market is driven by rise in pharmaceutical and biopharmaceutical production.
  • Moreover, rising prevalence of chronic diseases coupled with easy availability of ibuprofen across the globe is positively impacting the growth of the market during the forecast period.
  • The Global Ibuprofen Market is segmented based on product type, route of administration, application, age group, source, end-user, distribution channel, company, and region.

Bayer® Aspirin Partners with Leslie Odom Jr. and Family to Celebrate Heart Attack Survivors' Second Chance at Life

Retrieved on: 
Tuesday, June 15, 2021
Drugs, Brands, Health, Hepatotoxins, Nonsteroidal anti-inflammatory drugs, Aging-associated diseases, Aspirin, Commercialization of traditional medicines, Bayer, Myocardial infarction, Heart, Leslie Odom Jr.

WHIPPANY, N.J., June 15, 2021 /PRNewswire/ -- Bayer Aspirin partners with Leslie Odom Jr., singer and actor, to celebrate heart attack survivors and their second chance at life with a special song, called "Second Chance," inspired by Odom's father-in-law, Stuart K. Robinson, a heart attack survivor.

Key Points: 
  • WHIPPANY, N.J., June 15, 2021 /PRNewswire/ -- Bayer Aspirin partners with Leslie Odom Jr., singer and actor, to celebrate heart attack survivors and their second chance at life with a special song, called "Second Chance," inspired by Odom's father-in-law, Stuart K. Robinson, a heart attack survivor.
  • The song is part of the Bayer Aspirin campaign, "Your Heart Isn't Just Yours."
  • "Your heart belongs to the people who love you most, the people who need you in their life: your family and friends.
  • An aspirin regimen, if directed by a doctor, can help reduce the risk of another heart attack by 31%3.

Baum Hedlund Announces Leadership of California Zantac JCCP

Retrieved on: 
Tuesday, June 15, 2021
Chemical compounds, H2 receptor antagonists, Drugs, Furans, Hepatotoxins, Ranitidine, Thioethers, Organic compounds, Roundup

The Presiding Judge of the California Superior Court then assigned Judge Winifred Y. Smith as the Coordination Trial Judge.

Key Points: 
  • The Presiding Judge of the California Superior Court then assigned Judge Winifred Y. Smith as the Coordination Trial Judge.
  • Judge Smiths order appoints trial attorneys R. Brent Wisner of Baum Hedlund Aristei & Goldman and Jennifer Moore (also admitted to practice law in California) of the Moore Law Group to the Zantac JCCP leadership as Plaintiffs Liaisons.
  • With the federal Zantac MDL and the new Ranitidine Product Cases JCCP in California state court, we are following the same path that we took with Roundup, says Wisner.
  • Individuals diagnosed with various forms of cancer after regularly taking Zantac may be eligible to pursue a case in the California Ranitidine Product Cases JCCP 5150.

TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Hepatitis, Non-alcoholic fatty liver disease, Hepatotoxins, Clinical medicine, Comorbidity, Anatomy, Statin, Cardiovascular disease

"...Guideline-recommended statins remain underutilized and were not prescribed in 40% of NAFLD patients..." Anna Lok, MD

Key Points: 
  • "...Guideline-recommended statins remain underutilized and were not prescribed in 40% of NAFLD patients..." Anna Lok, MD
    Global prevalence of NAFLD is estimated at 25%, and diagnoses have increased over the past two decades.
  • 1 This increasing prevalence, paired with high risk of heart disease that NAFLD patients face, sets the stage for a growing public health concern.
  • Statins are a class of medications commonly prescribed to reduce the risk of heart disease.
  • 5 , 6
    "Providers are grappling with an aging population, paired with serious and comorbid chronic conditions like heart disease and NAFLD.